<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>▫$α$▫-heteroarylthiomethyl ketones</dc:title><dc:creator>Knez,	Damijan	(Avtor)
	</dc:creator><dc:creator>Proj,	Matic	(Avtor)
	</dc:creator><dc:creator>Bozovičar,	Krištof	(Avtor)
	</dc:creator><dc:creator>Gobec,	Stanislav	(Avtor)
	</dc:creator><dc:subject>SARS-CoV-2</dc:subject><dc:subject>3CLpro inhibitors</dc:subject><dc:subject>main protease</dc:subject><dc:subject>covalent inhibitors</dc:subject><dc:subject>ketones</dc:subject><dc:description>The main protease 3CL$^pro$ of the SARS-CoV-2 virus is a well- -established therapeutic target for the treatment of COVID19. In this study, we screened an in-house compound library and identified a series of α-heteroarylthiomethyl ketones as inhibitors of 3CLpro. Among these, analogues 31 and 33 emerged as the most interesting candidates with IC$_{50}$ values of 95.4 ± 3.1 and 95.0 ± 6.9 µmol L$^{-1}$, respectively. Preliminary in vitro studies suggest a potential covalent mode of inhibition, although further studies are required to confirm this mechanism. These findings provide a new chemical scaffold for the development of 3CL$^pro$-targeting inhibitors</dc:description><dc:date>2025</dc:date><dc:date>2025-06-30 07:55:44</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>169970</dc:identifier><dc:identifier>UDK: 578.834</dc:identifier><dc:identifier>ISSN pri članku: 1846-9558</dc:identifier><dc:identifier>DOI: 10.2478/acph-2025-0023</dc:identifier><dc:identifier>COBISS_ID: 240680451</dc:identifier><dc:language>sl</dc:language></metadata>
